ImmunityBio, Inc.
IBRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001326110
In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $351.4M (310.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 15, 2026 | Mar 3, 2025 | – | Feb 14, 2023 | – |
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K | $934.0K |
| Cost of revenue | $753.0K | $0 | – | – | – |
| Operating expenses | – | $358.9M | $362.9M | $351.5M | $331.2M |
| Research and development | – | $190.1M | $232.4M | $248.1M | $196.0M |
| Selling, general and administrative | – | $168.8M | $129.6M | $102.7M | $135.3M |
| Operating income | -$256.0M | -$344.2M | -$362.3M | -$351.3M | -$330.3M |
| Interest expense | $60.9M | $114.7M | $129.2M | $63.5M | $14.8M |
| Income tax | -$135.0K | $0 | -$40.0K | $34.0K | $9.00K |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M | -$346.8M |
| EPS, basic | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 |
| EPS, diluted | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
| Weighted shares, basic | 919.9M | 697.3M | 508.6M | 399.9M | 389.2M |
| Weighted shares, diluted | 919.9M | 700.4M | 508.6M | 399.9M | 389.2M |
| Margins and growth | |||||
| Operating margin | -226.0% | -2334.2% | -58239.5% | -146374.2% | -35361.9% |
| Net margin | -310.2% | -2804.8% | -93761.4% | -173569.6% | -37129.6% |
| Revenue growth, year over year | +668.3% | +2,270.6% | +159.2% | −74.3% | +741.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 15, 2026 | Mar 3, 2025 | – | Feb 14, 2023 | – |
| Cash and equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M |
| Short-term investments | $154.5M | $6.38M | $1.01M | $2.54M | $136.0M |
| Accounts receivable | $42.6M | $2.36M | – | – | – |
| Inventory | $910.0K | $8.27M | – | – | – |
| Total current assets | $314.9M | $184.6M | $294.1M | $140.6M | $334.3M |
| Property, plant and equipment | $114.3M | $137.1M | $146.1M | $143.7M | $82.9M |
| Goodwill | $910.0K | $910.0K | – | – | – |
| Intangible assets | $13.0M | $14.5M | $17.1M | $20.0M | $1.42M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M |
| Accounts payable | – | – | – | $21.0M | $11.4M |
| Short-term debt | $1.75M | – | – | – | – |
| Total current liabilities | $61.8M | $54.9M | $58.3M | $500.9M | $369.0M |
| Total liabilities | $1.00B | $871.1M | $1.09B | $812.2M | $712.8M |
| Shareholders' equity | -$499.6M | -$488.1M | -$585.9M | -$449.8M | -$243.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 15, 2026 | Mar 3, 2025 | – | Feb 14, 2023 | – |
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M |
| Capital expenditures | $3.85M | $6.89M | $30.6M | $78.2M | $33.6M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M | -$308.0M |
| Depreciation and amortization | $15.5M | $17.6M | $18.5M | $18.3M | $14.2M |
| Stock-based compensation | $36.8M | $34.4M | $49.2M | $40.2M | $57.2M |
| Share buybacks | – | – | – | – | $0 |
| Investing cash flow | -$149.8M | -$12.2M | -$30.5M | $27.3M | -$84.9M |
| Financing cash flow | $400.2M | $281.6M | $558.3M | $233.6M | $505.4M |
| Net change in cash | -$54.5M | -$121.9M | $160.8M | -$76.3M | $146.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 32.5% | 233.5% | 7904.0% | 16741.3% | 6122.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 1.06B | +8.0% | SEC |
| Jul 31, 2026 | 1.06B | +12.1% | SEC |
| May 5, 2026 | 1.05B | +18.7% | SEC |
| Feb 19, 2026 | 1.03B | +20.5% | SEC |
| Oct 30, 2025 | 985.0M | +41.3% | SEC |
| Jul 31, 2025 | 945.3M | +35.7% | SEC |
| May 8, 2025 | 882.6M | +27.6% | SEC |
| Feb 27, 2025 | 853.4M | +26.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.